Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients

American Journal of Therapeutics

Volumn 13, Issue 3, 2006, Pages 192-197

  Cleophas, T J ^a   Agrawal, R ^b   Lichtenthal, A ^b   Makel W ^c   Fici, F ^d  

^a ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^b Berlin Chemie AG   (Germany)

^c Clinical Research Facilities   (Netherlands)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Beta blockers; Efficacy safety study; Essential hypertension; Isolated systolic hypertension; Nebivolol

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEBIVOLOL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BORDERLINE HYPERTENSION; BRONCHOSPASM; CLINICAL TRIAL; COLD LIMB; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEART PALPITATION; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; WORLD HEALTH ORGANIZATION;

ADRENERGIC BETA-ANTAGONISTS; AMBULATORY CARE FACILITIES; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; ETHANOLAMINES; FEMALE; GERMANY; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 33745818342     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000149923.39085.44     Document Type: Article

References (24)

1. Oldenbroek C, Kaihlanan PM. The effect of nebivolol in the treatment of essential hypertension. A double-blind randomized comparison with placebo in an international dose-finding trial. JRF Clinical Research Report on NEB, International Network, August 1994.
2. Lacourcière Y. Multicenter clinical evaluation of antihypertensive efficacy and safety of nebivolol and hydrochlorothiazide: HANS (Hydrochlorothiazide and Nebivolol Study). JRF Clinial Research Report on NEB, Canadian Network, July 1994.
3. Van Nueten L, Uhlir O, Van Bortel LM. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomized trial. J Hum Hypertens. 1998;12:135-140.
4. Van Nueten L, Uhlir O, Van Bortel LM. A double-blind comparative trial of the effects of metoprolol and nebivolol in hypertensive patients. Drug Invest. 1991;3:S134-S136.
5. Van Nueten L. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther. 1998;5:237-243.
6. Stumpe K. Clinical evaluation of the antihypertensive efficacy and safety of nebivolol versus amlodipine in elderly patients with confirmed mild to moderate hypertension. JRF Clinical Research Report on NEB, German Network, May 1995.
7. Van Nueten L. Nebivolol versus enalapril in the treatment of essential hypertension: a double-blind randomized trial. J Hum Hypertens. 1997;11:813-819.
8. Lacourcière Y. A double-blind crossover comparison of nebivolol and lisinopril in the treatment of ambulatory hypertension. Am J Ther. 1994;1:74-80.
9. Cleophas TJ, Grabowsky I, Niemeijer MG, et al. Long-term efficacy of nebivolol monotherapy in patients with hypertension. Curr Ther Res. 2001;62:451-462.
10. Anonymous. Safety Assessment of Marketed Medicines (SAMM) guidelines. Br J Clin Pharmacol. 1994;38:95-97.
11. Swales JD, Sever PS, Peart WS. Evidence from trials. In: Swales JD, Sever PS, Peart WS, eds. Hypertension, New York: Gower Medical Publishing; 1991; 10.1-10.36.
12. Van Bortel LM. Pharmacological properties of nebivolol in man. Eur J Clin Pharmacol. 1997;51:37-38.
13. Cleophas TJ. Experimental evidence for selective antagonistic action of nebivolol on beta-1 adrenergic receptors. J Clin Med. 1998;2:1-8.
14. Cleophas TJ, Niemeyer MG, Kalmansohn RB, et al. Drug therapy: nebivolol. Neth Heart J. 2000;7:179-185.
15. Cleophas TJ, Van der Meulen J, Van Ouwerkerk B. Isolated systolic hypertension. Why is it so hard to treat. J Am Coll Ang. 2003;1:241-247.
16. Münzel TF. Nebivolol and endothelial dysfunction. Perfusion 2000;8:348-349.
17. Brehm BR, Bertsch D, Wolf SC. Nebivolol hemmt die Proliferation sowohl von humanen koronar arteriellen glatten Muskelzellen als auch von Endothelzellen und steigert die NO-freisetzung. Perfusion 1999;7:475-484.
18. Staessen JA, Fagard R, Thijs L, et al. For the Systolic hypertension in Europe (Syst-Eur) trial investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
19. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens. 1998;16:1823-1829.
20. Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. Effects of calcium-channel blockade in older patients with diabetes and isolated systolic hypertension. N Engl J Med. 1999;340:677-684.
21. Swales UJD, Sever PS, Peart SS. Clinical Atlas of Hypertension. New York: Gower Medical Publishing, 1999;1021.
22. Napoli C, Liguori A, De Nigris F, et al. Beneficial effect of nebivolol on the NO-pathway in essential hypertensive patients. Eur Heart J. 2002;23(Suppl 1):210.
23. Kouroedov A, Cosentino F, Francia P, et al. Nebivolol restores endothelium-dependent vasodilation and inhibits atherosclerosis in apolipoprotein E-deficient mice. Eur Heart J. 2003;24(Suppl 1): 319.
24. Tzemos N, Lin PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension, a randomized, double-blind, crossover study. Circulation. 2001;104:511-514.